Global Non-small Cell Lung Cancer Therapeutics Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Non-small Cell Lung Cancer Therapeutics market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Non-small Cell Lung Cancer Therapeutics market."
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.

The global Non-small Cell Lung Cancer Therapeutics market is valued at 6660 million US$ in 2018 is expected to reach 11900 million US$ by the end of 2025, growing at a CAGR of 7.5% during 2019-2025.
This report focuses on Non-small Cell Lung Cancer Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Non-small Cell Lung Cancer Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    GlaxoSmithKline
    Novartis
    AstraZeneca
    Roche
    Bristol-Myers Squibb
    Pfizer
    Eli Lilly
    Sanofi

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Alimta
    Iressa
    Avastin
    Tarceva
    Zykadia
    Tagrisso
    Xalkori
    Cyramza
    Opdivo
    Alecensa

Segment by Application
    Hospital
    Clinic